Ahmedabad-based Torrent Pharmaceuticals posted an 11% year-on-year rise in net profit for the quarter ended March 2025, riding on robust growth in its India business and margin expansion. Profit after tax came in at ₹498 crore, up from ₹449 crore in the same period last year. Adjusted for exceptional items, the quarterly net profit growth stood at 15%.

The drugmaker, part of the ₹45,000-crore Torrent Group, also announced a leadership transition. As part of a long-term succession strategy, Aman Mehta will take charge as Managing Director effective August 1, 2025. The company said the move is aimed at building a “future-ready leadership team” to deliver sustained value to stakeholders.

Torrent reported fourth-quarter revenue of ₹2,959 crore, reflecting an 8% year-on-year growth. Operating EBITDA rose by 9% to ₹964 crore with margins expanding to 32.6%. After adjusting for a one-time inventory revaluation impact, EBITDA stood at ₹981 crore with a margin of 33.1%.

India remained the growth engine for the company, with revenue rising 12% to ₹1,545 crore, outpacing the Indian Pharmaceutical Market (IPM) growth of 8% during the quarter. Torrent's chronic therapies segment grew 14%, and it now has 21 brands in IPM’s top 500, including 14 brands with sales exceeding ₹100 crore.

Torrent also recommended a final dividend of ₹6 per share, in addition to the interim dividend of ₹26 declared earlier in FY25.

In the international markets, performance was uneven. The U.S. business grew 15% year-on-year in rupee terms to ₹302 crore (10% in constant currency), while the German market reported modest growth of 2% to ₹286 crore. However, revenues from Brazil dipped 6% to ₹351 crore, largely due to depreciation of the Brazilian Real and softer-than-expected price hikes, although the company grew faster than the market in volume terms.

Full-year consolidated revenues stood at ₹11,516 crore, up 7% from the previous year. FY25 net profit rose 15% to ₹1,911 crore, while annual R&D spend grew 10% to ₹581 crore.

Torrent Pharma ranks seventh in the Indian pharmaceutical market and is among the top five in cardiovascular, gastro, CNS, and dermatology segments. With 76% of domestic revenue coming from chronic and sub-chronic therapies, the company maintains a sharp focus on speciality drugs. Its global footprint extends to over 50 countries, supported by eight manufacturing plants, five of which are approved by the U.S. FDA.